Pharmacologic target-mediated drug disposition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

170 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Meta-Analysis and Physiologically-Based Modeling of the Pharmacokinetics and Pharmacodynamics of Dexamethasone in Horses.Pharmaceutical research · 2026
   Pooled it
2. Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients.Journal of pharmacokinetics and pharmacodynamics · 2020
   Pooled it
3. Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers.Clinical and translational science · 2024
   Trial
4. Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial.Clinical and translational science · 2022
   Trial
5. A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults.Journal of clinical pharmacology · 2021
   Trial
6. Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500.Clinical and translational science · 2020
   Trial
7. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2019
   Trial
8. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.British journal of clinical pharmacology · 2019
   Trial
9. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.Pharmaceutical research · 2019
   Trial
10. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.Pharmaceutical research · 2017
    Trial
11. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).Journal of clinical pharmacology · 2017
    Trial
12. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.British journal of clinical pharmacology · 2012
    Trial
13. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.British journal of clinical pharmacology · 2012
    Trial
14. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.Journal of pharmacokinetics and pharmacodynamics · 2012
    Trial
15. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.Annals of the rheumatic diseases · 2011
    Trial
16. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.Leukemia & lymphoma · 2009
    Trial
17. Calculating Receptor Occupancy using TMDD Models - What has to be Considered?The AAPS journal · 2026
    Article
18. PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing.CPT: pharmacometrics & systems pharmacology · 2026
    Article
19. Rebinding drives cellular retention of small-molecule drugs with abundant targets.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
20. Binding Kinetics Can Explain Linear and Nonlinear Pharmacokinetics of Dipeptidyl Peptidase-IV Inhibitors Within a Single Target-Mediated Framework.Pharmaceutical research · 2026
    Article

110 more citing papers are in PubMed but not listed here.

Corrections and comments

• Commented on by
  Impact of target interactions on small-molecule drug disposition: an overlooked area.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as